195 related articles for article (PubMed ID: 35558086)
1. Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
Liang J; Hu F; Dan M; Sang Y; Abulikemu K; Wang Q; Hong Y; Kang X
Front Immunol; 2022; 13():825312. PubMed ID: 35558086
[TBL] [Abstract][Full Text] [Related]
2. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
Kabashima K; Matsumura T; Komazaki H; Kawashima M;
N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.
Igarashi A; Katsunuma T; Matsumura T; Komazaki H;
Br J Dermatol; 2023 Dec; 190(1):20-28. PubMed ID: 37522351
[TBL] [Abstract][Full Text] [Related]
4. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.
Kabashima K; Matsumura T; Komazaki H; Kawashima M;
Br J Dermatol; 2022 Apr; 186(4):642-651. PubMed ID: 34726262
[TBL] [Abstract][Full Text] [Related]
5. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
Silverberg JI; Pinter A; Pulka G; Poulin Y; Bouaziz JD; Wollenberg A; Murrell DF; Alexis A; Lindsey L; Ahmad F; Piketty C; Clucas A
J Allergy Clin Immunol; 2020 Jan; 145(1):173-182. PubMed ID: 31449914
[TBL] [Abstract][Full Text] [Related]
6. Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial.
Kabashima K; Matsumura T; Hayakawa Y; Kawashima M;
J Dermatolog Treat; 2023 Dec; 34(1):2177096. PubMed ID: 36779675
[TBL] [Abstract][Full Text] [Related]
7. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.
Snast I; Reiter O; Hodak E; Friedland R; Mimouni D; Leshem YA
Am J Clin Dermatol; 2018 Apr; 19(2):145-165. PubMed ID: 29098604
[TBL] [Abstract][Full Text] [Related]
8. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
Ruzicka T; Hanifin JM; Furue M; Pulka G; Mlynarczyk I; Wollenberg A; Galus R; Etoh T; Mihara R; Yoshida H; Stewart J; Kabashima K;
N Engl J Med; 2017 Mar; 376(9):826-835. PubMed ID: 28249150
[TBL] [Abstract][Full Text] [Related]
9. Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study.
Silverberg JI; Pinter A; Alavi A; Lynde C; Bouaziz JD; Wollenberg A; Murrell DF; Alpizar S; Laquer V; Chaouche K; Ahmad F; Armstrong JM; Piketty C
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1562-1568. PubMed ID: 33711179
[TBL] [Abstract][Full Text] [Related]
10. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.
Kabashima K; Furue M; Hanifin JM; Pulka G; Wollenberg A; Galus R; Etoh T; Mihara R; Nakano M; Ruzicka T
J Allergy Clin Immunol; 2018 Oct; 142(4):1121-1130.e7. PubMed ID: 29753033
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].
Kaneda N
Nihon Yakurigaku Zasshi; 2023; 158(3):282-289. PubMed ID: 37121713
[TBL] [Abstract][Full Text] [Related]
12. Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial.
Kabashima K; Matsumura T; Komazaki H; Kawashima M;
Dermatol Ther (Heidelb); 2023 Apr; 13(4):997-1011. PubMed ID: 36905481
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of systemic treatments on pruritus associated with atopic dermatitis: A systematic review in pediatric patients.
Kouwenhoven TA; van Muijen ME; van de Kerkhof PCM; de Jong EMGJ; Kamsteeg M; Seyger MMB
Pediatr Dermatol; 2024; 41(1):34-40. PubMed ID: 38018272
[TBL] [Abstract][Full Text] [Related]
14. Selection of Nemolizumab Clinical Dosage for Atopic Dermatitis.
Wagner N; Loprete L; Duval V; Jauslin P; Benkali K; Silverberg JI; Wollenberg A; Saito T; Ahmad F; Graeber M; Winkelman W; Piketty C
J Drugs Dermatol; 2023 Oct; 22(10):1017-1020. PubMed ID: 37801534
[TBL] [Abstract][Full Text] [Related]
15. Effects of systemic therapies on pruritus in adults with atopic dermatitis: a systematic review and meta-analysis.
Tan XL; Thomas BR; Tan YJ; O'Toole EA
Clin Exp Dermatol; 2022 Apr; 47(4):658-666. PubMed ID: 34643956
[TBL] [Abstract][Full Text] [Related]
16. Nemolizumab for atopic dermatitis.
Labib A; Vander Does A; Yosipovitch G
Drugs Today (Barc); 2022 Apr; 58(4):159-173. PubMed ID: 35412530
[TBL] [Abstract][Full Text] [Related]
17. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study.
Kinugasa E; Igawa K; Shimada H; Kondo M; Funakoshi S; Imada N; Itami N; Fukazawa N; Takubo R; Kawata Y; Murota H
Clin Exp Nephrol; 2021 Aug; 25(8):875-884. PubMed ID: 33754202
[TBL] [Abstract][Full Text] [Related]
18. Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study.
Mihara R; Kabashima K; Furue M; Nakano M; Ruzicka T
J Dermatol; 2019 Aug; 46(8):662-671. PubMed ID: 31166620
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Li C; Sun X; Zhao K; Meng F; Li L; Mu Z; Han X
Dermatology; 2022; 238(4):725-735. PubMed ID: 34455413
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
Wang FP; Tang XJ; Wei CQ; Xu LR; Mao H; Luo FM
J Dermatol Sci; 2018 May; 90(2):190-198. PubMed ID: 29472119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
